Public health experts are concerned that, if confirmed, Donald Trump’s choice for secretary of the Department of Health and Human Services (HHS) – Robert F Kennedy Jr – could upend access to pharmaceutical drugs in favor of more experimental treatments.
Kennedy, who the president-elect picked earlier this month, has repeatedly expressed distrust for pharmaceuticals, and criticized the FDA for its “aggressive suppression of psychedelics”. On his podcast, he called the US “the sickest country in the world”, blaming its healthcare system for devoting billions to “the pills and the potions and the powders rather than on actually getting people healthy, building their immune systems”.
Kennedy is a surprising choice for a number of reasons. He’s an attorney who lacks government public health experience and has criticized Trump harshly during his own independent presidential campaign.
But, like Trump’s other cabinet picks, Kennedy has expressed a conspiratorial mistrust for the agency he’s nominated to run. Matt Gaetz, who had been tapped to become attorney general before withdrawing himself from consideration on Thursday, believes the January 6 insurrection was a government sham intended to cover a stolen election while Tulsi Gabbard, Trump’s national intelligence pick, has parroted Russian propaganda about US intelligence.
Kennedy has likewise promoted conspiracy theories about the healthcare system he would oversee, including the debunked theory that vaccines cause autism. Even the New York Post, which has praised Kennedy in the past, warned in an editorial board opinion that Kennedy’s confirmation would be disastrous for public health, citing a 2023 interview when “he told us with full conviction that all America’s chronic health problems began in one year in the 1980s.”
Reshma Ramachandran, a physician and director of the Yale Collaboration for Regulatory Rigor, Integrity, and Transparency, says that Kennedy’s theories are “tricky”, because they often contain a mix of truth and conspiracy. Like Kennedy, her team has raised concern about “the corporate influence at federal agencies, and how that might unduly affect regulatory decision making”. Similarly, there is some scientific evidence behind Kennedy’s concerns about the health impact of processed foods – but not his claims that a better diet would solve a plethora of physical and mental health issues.
Ramachandran says Kennedy’s seeming disregard for scientific evidence is deeply concerning.
“Having a healthy skeptic [as HHS secretary] is totally fine,” she said, “but that skepticism needs to come with at least some humility.”
During his campaign, Kennedy repeatedly villainized Adderall and SSRIs, and claimed that, if elected, he would legalize cannabis and use the tax revenue to create “wellness farms” where “we’re going to repair people” with addiction, including to “psychiatric drugs” such as “Adderall”. People who rely on Adderall and SSRIs are worried Kennedy might criminalize their medications.
As HHS secretary, Kennedy would have “quite a bit of power” to upend the healthcare system, says Ramachandran.
While traditionally, HHS defers to agencies such as the FDA, “there may be instances where they have the authority to override agencies.” Ramachandran explained that Kennedy would face legal challenges if he attempted to change the legal status of Adderall, for example, but that he is an expert in liability law and theoretically, he could do it.
Ramachandran is especially concerned that Kennedy will overturn recent FDA decisions he’s criticized: in 2020, the FDA pulled hydroxychloroquine as a Covid-19 treatment, citing safety concerns and lack of evidence. This year, the agency rejected Lykos Therapeutics’ MDMA assisted therapy for PTSD. Lykos hid adverse affects, including suicide attempts, in their clinical trial results. The trial was already plagued with ethical issues, including a sexual relationship between a therapist and a trial participant, who alleged it was assault. Notably, MDMA increases suggestibility.
Neşe Devenot, a bioethics researcher affiliated with Johns Hopkins University and the psychedelic harm reduction non-profit Psymposia, organized opposition to Lykos’s treatment. Their research found “the therapy component was based on pseudoscience very similar to Facilitated Communication,” a discredited technique ostensibly intended to help disabled people communicate, that actually gives their “facilitator” power to speak for them.
Kennedy boosted claims that Devenot’s opposition stemmed from hatred toward veterans, and blasted the FDA’s decision, suggesting it illustrated collusion with the pharmaceutical industry.
after newsletter promotion
But Lykos actually has close ties with the established pharmaceutical industry. Jeff George, Lykos’s chairperson, is also on the board of Amneal Pharmaceuticals, a company that makes a variety of traditional drugs, including generic Adderall.
Much of Kennedy’s rhetoric on psychedelics and the pharmaceutical industry echoes that of Elon Musk’s, who Trump has also tapped to join his cabinet. Devenot thinks that Kennedy is heavily influenced by Silicon Valley’s “move fast, break things” ethos around psychedelics – which Musk and others in the tech industry claim are superior to traditional mental health treatments.
Both Devenot and Ramachandran believe psychedelic therapies do have potential – but need more rigorous research.
Ramachandran says if Kennedy chooses to rush approval of Lykos’s therapy or other psychedelic treatments, it could backfire, because accelerated approvals lead to more safety issues.
Devenot can see why it’s appealing to think that psychedelics could be a “miracle solution” for all mental health ills, if only men like Kennedy and Musk could get the FDA out of the way.
“It’s a very reductive way of looking at mental health,” Devenot said, “the reality is a lot more complicated.”
